UWTASP tele-antimicrobial stewardship program | echo

July 25, 2017

Robert Cybulski, PhD
Marisa D'Angeli, MD
Rupali Jain, PharmD
John Lynch, MD
Natalia Martinez-Paz, MA, MPA
Paul Pottinger, MD

Agenda

- Didactic: *Skin and Soft Tissue Infections*
- Case Discussion
- Open Discussion

URL: http://rwpoll.com
Code: uwecho

FRONTLINE

WATCH SCHEDULE INVESTIGATIONS

NEXT ON FRONTLINE

UW TASP tele-antimicrobial stewardship program | echo

Skin and Soft Tissue Infections Part 1

John Lynch, MD, MPH
Associate Professor
Harborview Medical Center &
The University of Washington School of Medicine

July 25, 2017

URL: http://rwpoll.com
Code: uwecho

This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.

Skin and Soft Tissue Infections (SSTI)

- 2nd most common reason for hospitalization
- >700,000 hospitalizations per year
- ~65% increase since 1999
- Inappropriately broad and lengthy abx are common
- Appropriate therapy associate with improved outcomes
- Novel therapies are….unknown
- Best plan is optimizing the use of known therapies, including antimicrobials

RESEARCH ARTICLE Open Access

Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients

Thomas L. Walsh[1,2*], Lynn Chan[3], Chelsea I. Konopka[3], Michael J. Burkitt[4,5], Matthew A. Moffa[1,2], Derek N. Bremmer[6], Monika A. Murillo[1,2], Courtney Watson[7] and Noreen H. Chan-Tompkins[3]

RESEARCH ARTICLE Open Access

Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients

Thomas L. Walsh[1,2*], Lynn Chan[3], Chelsea I. Konopka[3], Michael J. Burkitt[4,5], Matthew A. Moffa[1,2], Derek N. Bremmer[6], Monika A. Murillo[1,2], Courtney Watson[7] and Noreen H. Chan-Tompkins[3]

Background: Skin and soft tissue infections (SSTIs) are a leading cause for hospitalizations in the United States. Few studies have addressed the appropriateness of antibiotic therapy in the management of SSTIs without complicating factors. We aimed to determine the appropriateness of antibiotic treatment duration for hospitalized adult patients with uncomplicated SSTIs.

Methods: This was a retrospective analysis performed at two academic medical centers in Pittsburgh, Pennsylvania on patients aged 18 years and older with primary ICD-9 code for SSTIs admitted August 1st, 2014–March 31st, 2015. The primary outcome was the appropriateness of antibiotic treatment duration for uncomplicated SSTIs. Secondary objectives included the appropriateness of antibiotic agent spectrum, duration of inpatient length of stay (LOS), utilization of blood cultures and advanced imaging modalities, and re-hospitalization for SSTI within 30 days of discharge from the index admission.

Results: A total of 163 episodes were included in the cohort. The mean duration of total antibiotic therapy was 12.6 days. Appropriate duration was defined as receipt of total antibiotic duration of less than 10 days and occurred in 20.2% of patients. Twenty eight percent of patients received antibiotics for greater than 14 days. Seventy three (44.8%) patients received greater than 24 h of inappropriate extended spectrum gram-negative coverage; 65 (39.9%) received anaerobic coverage.

Conclusions: In the majority of patients, treatment duration was excessive. Inappropriate broad spectrum antibiotic selection was utilized with regularity for SSTIs without complicating factors. The management of uncomplicated SSTIs represents a significant opportunity for antimicrobial stewardship.

Avoidable Antibiotic Exposure for Uncomplicated Skin and Soft Tissue Infections in the Ambulatory Care Setting

Hermione J. Hurley, MBChB,[a,d] Bryan C. Knepper, MSc, MPH,[b] Connie S. Price, MD,[a,c,d,e] Philip S. Mehler, MD,[a,b,c,e] William J. Burman, MD,[a,c,d,e] Timothy C. Jenkins, MD[a,c,d,e]

[a]Department of Medicine, [b]Department of Patient Safety and Quality, [c]Division of Infectious Diseases, Denver Health Medical Center, Denver, Colo; [d]Department of Medicine, [e]Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colo.

CLINICAL SIGNIFICANCE

- Approximately half of uncomplicated skin infections were associated with avoidable antibiotic exposure, defined as the use of antibiotics with broad gram-negative activity, combination antibiotic therapy, or treatment for 10 or more days.
- Use of a short-course, single-antibiotic treatment strategy would reduce total antibiotic exposure by up to 55%.
- Uncomplicated skin infections are an important target for future antimicrobial stewardship interventions.

Table 4 Avoidable Antibiotic Exposure in 292 Cases with Complete Prescribing Data*

	Cellulitis n = 116	Wound Infection n = 33	Abscess n = 143	Total n = 292
Total cases with avoidable antibiotic exposure	60 (52)	17 (52)	58 (41)	135 (46)
Antibiotics with a broad spectrum of gram-negative activity	5 (4)	3 (9)	3 (2)	11 (4)
Combination antibiotic therapy	15 (13)	8 (24)	12 (8)	35 (12)
Treatment for ≥10 d	54 (47)	12 (36)	56 (39)	122 (42)

*Analysis excludes 72 cases where an antibiotic was prescribed but the duration of therapy could not be determined.

Contents lists available at ScienceDirect

American Journal of Infection Control

journal homepage: www.ajicjournal.org

Major Article

Antimicrobial stewardship in the treatment of skin and soft tissue infections

Julie A. Gibbons RN, BSN [a], Hayden L. Smith PhD [a,*], Sudhir C. Kumar MD [a], Katherine Johnson Duggins PharmD [b], Amanda M. Bushman PharmD [a], Jayme M. Danielson DO [c], William J. Yost MD [a], Jonathan J. Wadle BA [d]

[a] *UnityPoint Health—Des Moines, Des Moines, IA*
[b] *Bryan Health, Lincoln, NE*
[c] *Douglas County Hospital, Alexandria, MN*
[d] *Des Moines University, Des Moines, IA*

Contents lists available at ScienceDirect

American Journal of Infection Control

journal homepage: www.ajicjournal.org

Major Article

Antimicrobial stewardship in the treatment of skin and soft tissue infections

Julie A. Gibbons RN, BSN [a], Hayden L. Smith PhD [a,*], Sudhir C. Kumar MD [a], Katherine Johnson Duggins PharmD [b], Amanda M. Bushman PharmD [a], Jayme M. Danielson DO [c], William J. Yost MD [a], Jonathan J. Wadle BA [d]

[a] UnityPoint Health—Des Moines, Des Moines, IA
[b] Bryan Health, Lincoln, NE
[c] Douglas County Hospital, Alexandria, MN
[d] Des Moines University, Des Moines, IA

The study intervention was initiated at the beginning of the prospective period. The intervention phase included an initial presentation to internal medicine staff physicians and residents by a national SSTI guest speaker, followed by the implementation of a new SSTI evidence-based treatment algorithm (supplementary fig S1). Additionally, just in time provider education was conducted, which included phone calls and paper-electronic medical record notes targeted at physicians not adhering to the treatment algorithm. Passive provider education about the treatment algorithm was used via hospital newsletters, handouts, and displayed posters throughout breakrooms and messaging boards. The study team included an internal medicine resident, pharmacy resident, nurse epidemiologist, graduate medicine faculty (infectious disease physician), residency program director, and epidemiology trained researcher.



Types of SSTI

- Erysipelas
- Impetigo
- Cellulitis
- Necrotizing skin and soft tissue infection (and Fournier's gangrene)
- Furuncle and carbuncle (diff than folliculitis)
- Cutaneous abscess
- Pyomyositis
- Gas gangrene
- Wound infections….

SSTI: Most Common Organisms

- Aerobic Gram-positive bacteria
- *Staphylococcus aureus* (MSSA and MRSA)
  - Purulent SSTI like abscesses and wound infections
- *Streptococcus pyogenes (*aka Group A strep)
  - Non-purulent SSTIs like cellulitis
- *Vibrio vulnificis,* aeromonas, peptostreptococcus, clostridia species
- Polymicrobial infections


Thick (hairless) skin
Thin (hairy) skin
Hair shaft
Opening of sweat duct
Epidermis
Dermal papillae
Superficial arteriovenous plexus
Papillary dermis
Dermis
Reticular dermis
Arrector pili muscle
Meissner's corpuscle
Sebaceous gland
Sweat duct
Subcutis/hypodermis
Deep arteriovenous plexus
Subcutaneous fat
Hair follicle
Eccrine sweat duct
Dermal nerve fibres
Eccrine sweat gland
Eccrine sweat gland
Pacinian corpuscle

Erysipelas

- Legs, toes, arms, face
- Upper dermis and lymphatics
- More superficial than cellulitis, well demarcated
- Usually GAS, sometimes Group B strep (*S. agalactiae)*
- Can recur
- TX: penicillin/1st gen ceph



Erysipelas

- Legs, toes, arms, face
- Upper dermis and lymphatics
- More superficial than cellulitis, well demarcated
- Usually GAS



Impetigo

- Superficial skin
- More common in children
- Usually a sore near mout or nose
- Honey-colored scab
- *S. aureus* or *S. pyogenes*
- Contagious
- TX: cephalexin or diclox



Cellulitis

- Involves dermis and subcutaneous fat
- Area of redness usually not sharp
- Usually painful
- Can be edematous
- May involve lymphatics
- Micro diagnosis usually not possible
- Hospitalized pts: eval for NSTI



36 yo healthy woman with area of tender, erythema on right forearm. Afebrile, no other symptoms, no other PMH.

Antimicrobial treatment?

A. Yes, TMP-SMX
B. No, nothing
C. Yes, amoxicillin-clavulanate
D. Yes, TMP-SMX and cephalexin
E. Yes, cephalexin

JAMA | Original Investigation

Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis
A Randomized Clinical Trial

Gregory J. Moran, MD; Anusha Krishnadasan, PhD; William R. Mower, MD, PhD; Fredrick M. Abrahamian, DO; Frank LoVecchio, DO; Mark T. Steele, MD; Richard E. Rothman, MD, PhD; David J. Karras, MD; Rebecca Hoagland, MS; Stephanie Pettibone, BS; David A. Talan, MD

DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, randomized superiority trial in 5 US emergency departments among outpatients older than 12 years with cellulitis and no wound, purulent drainage, or abscess enrolled from April 2009 through June 2012. All participants had soft tissue ultrasound performed at the time of enrollment to exclude abscess. Final follow-up was August 2012.

INTERVENTIONS Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice daily, for 7 days (n = 248 participants) or cephalexin plus placebo for 7 days (n = 248 participants).

MAIN OUTCOMES AND MEASURES The primary outcome determined a priori in the per-protocol group was clinical cure, defined as absence of these clinical failure criteria at follow-up visits: fever; increase in erythema (>25%), swelling, or tenderness (days 3-4); no decrease in erythema, swelling, or tenderness (days 8-10); and more than minimal erythema, swelling, or tenderness (days 14-21). A clinically significant difference was defined as greater than 10%.

JAMA | Original Investigation

Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis
A Randomized Clinical Trial

Gregory J. Moran, MD; Anusha Krishnadasan, PhD; William R. Mower, MD, PhD; Fredrick M. Abrahamian, DO; Frank LoVecchio, DO; Mark T. Steele, MD; Richard E. Rothman, MD, PhD; David J. Karras, MD; Rebecca Hoagland, MS; Stephanie Pettibone, BS; David A. Talan, MD

Figure 2. Clinical Cure Rates Among Participants With Cellulitis Treated With Cephalexin Plus Trimethoprim-Sulfamethoxazole or Cephalexin Plus Placebo in the Modified Intention-to-Treat, Per-Protocol, and FDA Guidance Early End-Point Populations

Study Population	Clinical Cure, No./Total (%): Cephalexin Plus Trimethoprim-Sulfamethoxazole	Clinical Cure, No./Total (%): Cephalexin Plus Placebo	Mean Difference, % (95% CI)	*P* Value
Per protocol	182/218 (83.5)	165/193 (85.5)	-2.0 (-9.7 to 5.7)	.50
mITT-1	189/248 (76.2)	171/248 (69.0)	7.3 (-1.0 to 15.5)	.07
mITT-2	202/241 (83.8)	198/239 (82.8)	1.0 (-6.1 to 8.1)	.85
FDA guidance early end point	63/237 (26.6)	62/233 (26.6)	0.0 (-8.4 to 8.4)	.94



IDSA GUIDELINE

Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America

Dennis L. Stevens,[1] Alan L. Bisno,[2] Henry F. Chambers,[3] E. Patchen Dellinger,[4] Ellie J. C. Goldstein,[5] Sherwood L. Gorbach,[6] Jan V. Hirschmann,[7] Sheldon L. Kaplan,[8] Jose G. Montoya,[9] and James C. Wade[10]

[1]Division of Infectious Diseases, Department of Veterans Affairs, Boise, Idaho; [2]Medical Service, Miami Veterans Affairs Health Care System, Florida; [3]San Francisco General Hospital, University of California; [4]Division of General Surgery, University of Washington, Seattle; [5]University of California, Los Angeles, School of Medicine, and R. M. Alden Research Laboratory, Santa Monica, California; [6]Department of Community Health, Tufts University, Boston, Massachusetts; [7]Medical Service, Puget Sound Veterans Affairs Medical Center, Seattle, Washington; [8]Department of Pediatrics, Baylor College of Medicine, Houston, Texas; [9]Department of Medicine, Stanford University, California; and [10]Geisinger Health System, Geisinger Cancer Institute, Danville, Pennsylvania


MANAGEMENT OF SSTIs
NONPURULENT
Necrotizing Infection /Cellulitis /Erysipelas
PURULENT
Furuncle / Carbuncle / Abscess
Severe
Moderate
Mild
Severe
Moderate
Mild
➢EMERGENT SURGICAL INSPECTION / DEBRIDEMENT
►Rule out necrotizing process
➢EMPIRIC Rx
• Vancomycin PLUS Piperacillin/Tazobactam
INTRAVENOUS Rx
• Penicillin or
• Ceftriaxone or
• Cefazolin or
• Clindamycin
ORAL Rx
• Penicillin VK or
• Cephalosporin or
• Dicloxacillin or
• Clindamycin
I & D C & S
I & D C & S
I & D
C & S
Moderate: signs of infection
Severe: failure of therapy or +SIRS
EMPIRIC Rx[1]
• Vancomycin or
• Daptomycin or
• Linezolid or
• Televancin or
• Ceftaroline
EMPIRIC Rx
• TMP/SMX or
• Doxycycline
DEFINED Rx
MRSA
• See Empiric
MSSA
• Nafcillin or
• Cefazolin or
• Clindamycin
DEFINED Rx
MRSA
• TMP/SMX
MSSA
• Dicloxacillin or
• Cephalexin
DEFINED Rx (Necrotizing Infections)
Monomicrobial Streptococcus pyogenes
• Penicillin PLUS Clindamycin
Clostridial sp.
• Penicillin PLUS Clindamycin
Vibrio vulnificus
• Doxycycline PLUS Ceftazidime
Aeromonas hydrophila
• Doxycycline PLUS Ciprofloxacin
Polymicrobial
• Vancomycin PLUS Piperacillin/Tazobactam
[1]Since daptomycin and televancin are not approved for use in children, vancomycin is recommended; clindamycin may be used if clindamycin resistance is <10-15% at the institution.